White Paper from Premier Research Reviews how to Optimize Country Selection in Oncology Clinical Trials
News Jun 04, 2010
Premier Research Group Limited, an international CRO with significant oncology research experience and expertise, released a new white paper, available at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, that reviews a funnel-approach to selecting target countries for oncology trials.
A challenging reality in the field of oncology clinical research exists in that only a very small percentage of adult cancer patients participate in clinical research studies. This reality slows the progression and approval of new therapies for the treatment of cancer. Over the last decade an extensive amount of research has been directed at identifying the reasons for low enrollment of adult cancer patients into clinical trials.
This new white paper reviews a country selection strategy, not directed at systemically improving upon the low percentage of oncology trial participation, but rather it acknowledges this paradigm and positions cancer trials for success despite this reality.
Copies of the white paper will be available at the 2010 ASCO Annual Meeting, booth 22076 or can be downloaded from the Premier Research website.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019